Chimeric (ASX:CHM) share price edges lower despite positive update Aaron Teboneras | April 22, 2021 2:23pm | More on: The Established in 2020, Chimeric is developing a breakthrough cancer cell therapy drug for solid tumours. The company uses chlorotoxin, which comes from scorpion venom, to bind and direct T cells to target glioblastoma (GBM). Initial scientific research conducted at the City of Hope Cancer Centre in Los Angeles found promising anti-tumour activity from CAR T therapy. At the time of writing, the biotechnology company’s shares are going for 29 cents apiece, down 1.6%. What did Chimeric announce? Investors appear unfazed by the company’s latest update, sending Chimeric shares lower.